Another meta-analysis came to a similar conclusion, namely that rifamycin-containing regimens taken for 3 months or longer had a better profile in preventing TB reactivation. Research
There is some evidence from animal and clinical studies that suggests that moxifloxacin-containing regimens as short as four months may be as effective as six months of conventional therapy.Bayer is currently running a phase II clinical trial in collaboration with the TB Alliance to evaluate shorter treatment regimens for TB; encouragingly, Bayer have also promised that if the trials are successful, Bayer will make moxifloxacin affordable and accessible in countries that need it. Another approach for anti-TB drug development, which does not rely on antibiotics, consists of targeting NAD+ synthase, an essential enzyme in tuberculosis bacteria but not in humans. Low level laser therapy for treating tuberculosis is not supported by reliable evidence. History
Streptomycin and para-aminosalicylic acid were developed by the mid-1940s. In 1960, Edinburgh City Hospital physician Sir John Crofton, addressed the Royal College of Physicians in London with a lecture titled "Tuberculosis Undefeated", and proposed that "the disease could be conquered, once and for all". With his colleagues at Edinburgh, he recognised that germs that developed only a mild resistance to one drug was significant. His team showed that when treating new cases of TB, strict compliance to a combination of three therapies, or the triple therapy, (streptomycin, para-aminosalicylic acid and isoniazid) could provide a complete cure. It became known as the Edinburgh method and became standard treatment for at least 15 years.
Diagnosis
Types
Genetic changes are related to the following types of Stickler syndrome:
Stickler syndrome, COL2A1 (75% of Stickler cases)
Stickler syndrome, COL11A1
Stickler syndrome, COL11A2(non-ocular)
Stickler syndrome, COL9A1 (recessive variant)
Stickler syndrome, COL9A2 (recessive variant)
Stickler syndrome, COL9A3 (recessive variant)
Stickler Syndrome, LOX3   (Recessive, 7 cases reported)Whether there are two or three types of Stickler syndrome is controversial. Each type is presented here according to the gene involved. The classification of these conditions is changing as researchers learn more about the genetic causes. Treatment
Many professionals that are likely to be involved in the treatment of those with Sticklers syndrome, include anesthesiologists, oral and maxillofacial surgeons; craniofacial surgeons; ear, nose, and throat specialists, ophthalmologists, optometrists, audiologists, speech pathologists, occupational therapists, physical therapists and rheumatologists. History
Scientists associated with the discovery of this syndrome include:
B. David (medicine)
Gunnar B. Stickler
G. Weissenbacher
Ernst Zweymüller

See also
Mandy Haberman, invented the Haberman Feeder
Marshall syndrome
Pierre Robin syndrome

References
External links

GeneReviews/NCBI/NIH/UW entry on Stickler Syndrome